Linatin 5mg Tablet contains Linagliptin 5mg, a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. Linagliptin works by enhancing the levels of incretin hormones, which increase insulin secretion and decrease glucagon release in a glucose-dependent manner, thereby improving glycemic control. It is prescribed as an adjunct to diet and exercise to improve glycemic parameters in adults with type 2 diabetes, either as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin. Linatin 5mg Tablet is characterized by its once-daily oral administration and favorable pharmacokinetic profile, including minimal renal excretion, making it suitable for patients with varying degrees of renal impairment without dose adjustment. Clinical studies have demonstrated its efficacy in reducing HbA1c levels with a low risk of hypoglycemia and weight neutrality. Common adverse effects may include nasopharyngitis, headache, and upper respiratory tract infections, though it is generally well tolerated. Linatin should be used cautiously in patients with a history of pancreatitis and monitored regularly to assess therapeutic response and safety. It is contraindicated in patients with type 1 diabetes or diabetic ketoacidosis.